Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Net Cash Flow: 2023-2025

Historic Net Cash Flow for Immunocore Holdings (IMCR) over the last 3 years, with Sep 2025 value amounting to $2.7 million.

  • Immunocore Holdings' Net Cash Flow fell 87.01% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$54.4 million, marking a year-over-year decrease of 176.11%. This contributed to the annual value of $14.8 million for FY2024, which is 53.51% down from last year.
  • Latest data reveals that Immunocore Holdings reported Net Cash Flow of $2.7 million as of Q3 2025, which was up 441.28% from -$780,000 recorded in Q2 2025.
  • Immunocore Holdings' 5-year Net Cash Flow high stood at $391.0 million for Q1 2024, and its period low was -$327.7 million during Q2 2024.
  • For the 3-year period, Immunocore Holdings' Net Cash Flow averaged around $5.6 million, with its median value being $10.2 million (2023).
  • The largest annual percentage gain for Immunocore Holdings' Net Cash Flow in the last 5 years was 2,758.78% (2024), contrasted with its biggest fall of 3,304.04% (2024).
  • Quarterly analysis of 3 years shows Immunocore Holdings' Net Cash Flow stood at -$12.3 million in 2023, then slumped by 461.17% to -$69.0 million in 2024, then slumped by 87.01% to $2.7 million in 2025.
  • Its Net Cash Flow stands at $2.7 million for Q3 2025, versus -$780,000 for Q2 2025 and $12.7 million for Q1 2025.